Search

Your search keyword '"Poel, M"' showing total 493 results
Start Over Author "Poel, M"
493 results on '"Poel, M"'

1. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

Author

Janssen, J. J. W. M., Löwenberg, B., Manz, M., Biemond, B. J., Westerweel, P. E., Klein, S. K., Fehr, M., Sinnige, H. A. M., Efthymiou, A., Legdeur, M. C. J. C., Pabst, T., Gregor, M., van der Poel, M. W. M., Deeren, D., Tick, L. W., Jongen-Lavrencic, M., van Obbergh, F., Boersma, R. S., de Weerdt, O., Chalandon, Y., Heim, D., Spertini, O., van Sluis, G., Graux, C., Stüssi, G., van Norden, Y., and Ossenkoppele, G. J.

Published
2022
Full Text
View/download PDF

3. Build up of off-diagonal long-range order in microcavity exciton-polaritons across the parametric threshold

Author

Spano, R., Cuadra, J., Lingg, C., Sanvitto, D., Martin, M. D., Eastham, P. R., van der Poel, M., Hvam, J. M., and Vina, L.

Subjects
Condensed Matter - Mesoscale and Nanoscale Physics, Condensed Matter - Materials Science
Abstract

We report an experimental study of the spontaneous spatial and temporal coherence of polariton condensates generated in the optical parametric oscillator configuration, below and at the parametric threshold, and as a function of condensate area. Above the threshold we obtain very long coherence times (up to 3 ns) and a spatial coherence extending over the entire condensate (40 \mu m). The very long coherence time and its dependence on condensate area and pump power reflect the suppression of polariton-polariton interactions by an effect equivalent to motional narrowing., Comment: 5 pages, 3 figures

Published
2011

8. Cognitive functioning in survivors of hematopoietic stem cell transplantation compared with a matched general population sample: The MOSA study

Author

Wauben, B., van der Poel, M. W. M., Greevenbroek, M. M. J., van Yperen, N. C., Schram, M. T., van Boxtel, M. P. J., Sastry, M., Simons, S. O., Stehouwer, C. D. A., Dagnelie, P. C., Wesselius, A., Schouten, H. C., Köhler, S., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, MUMC+: HVC Pieken Maastricht Studie (9), Psychology 2, Section Neuropsychology, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: FPN NPPP I, RS: NUTRIM - R3 - Respiratory & Age-related Health, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), MUMC+: MA Interne Geneeskunde (3), RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, and Psychology 5

Abstract

BACKGROUND: Although cognitive problems can recover over time, a subgroup of hematopoietic stem cell transplantation (HCT) survivors experiences persistent cognitive problems in the long-term. Despite these implications, studies assessing cognitive functioning in HCT survivors are limited. OBJECTIVES: The aim of the present study was (1) to quantify the prevalence of cognitive impairment in patients treated with HCT who survived at least 2 years, and to compare these with a matched reference group representing the general population; (2) to identify potential determinants of cognitive functioning within the HCT survivor group. STUDY DESIGN: Within the single-centre Maastricht Observational study of late effects after Stem cell trAnsplantation (MOSA) cognitive performance was assessed by a neuropsychological test battery divided into three cognitive domains respectively memory, information processing speed, and executive function & attention. An overall cognition score was calculated as the average of the domain scores. A total of 115 HCT survivors were group-matched on a 1:4 ratio to the reference group by age, sex, and level of education. Regression analyses adjusted for different sets of covariates including demographic, health- and lifestyle-related factors were used to test for differences in cognition between HCT survivors and the reference group resembling the general population. A limited set of clinical characteristics (diagnosis, type of transplant, time since treatment, conditioning regimen with TBI and age at time of transplant) were assessed as potential determinants of neurocognitive dysfunction among HCT survivors. Cognitive impairment was defined as scores in the cognitive domains < -1.5 SD from what can be expected based on someone's age, sex, and education. RESULTS: The mean age at time of transplant was 50.2 (SD 11.2) years, and the mean number of years after transplant was 8.7 (SD 5.7) years. The majority of HCT survivors were treated with autologous HCT (N = 73; 64%). The prevalence of cognitive dysfunction in HCT survivors was 34.8%, and 21.3% in the reference group (p = .002.) When adjusted for age, sex, and level of education HCT survivors had a worse overall cognition score (b=-.35, 95%CI=-.55, -.16, p

Published
2023

9. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Author

Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., and Löwenberg, B.

Published
2020
Full Text
View/download PDF

10. OS03.6.A Rituximab in primary CNS lymphoma - long term follow-up of the phase III HOVON 105/ALLG NHL 24 Study

Author

Bromberg, J E C, primary, Issa, S, additional, van der Holt, B, additional, Minnema, M C, additional, Seute, T, additional, Durian, M F, additional, Cull, G, additional, van der Poel, M W M, additional, Stevens, W B C, additional, Zijlstra, J M, additional, Nijland, M, additional, Mason, K D, additional, Beeker, A, additional, Brandsma, D, additional, van den Bent, M J, additional, Gonzalez, M, additional, de Jong, D, additional, and Doorduijn, J K, additional

Published
2022
Full Text
View/download PDF

11. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, Carlos, Stüssi, G, van Norden, Y, Ossenkoppele, G J, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, Carlos, Stüssi, G, van Norden, Y, and Ossenkoppele, G J

Abstract

Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML patients > 65 years of age (median 69 (65-80)) were randomly assigned to standard chemotherapy (3 + 7) with or without oral selinexor 60 mg twice weekly (both arms n = 51), days 1-24. In the second cycle, cytarabine 1000 mg/m twice daily, days 1-6 with or without selinexor was given. CR/CRi rates were significantly higher in the control arm than in the investigational arm (80% (95% C.I. 69-91%) vs. 59% (45-72%; p = 0.018), respectively). At 18 months, event-free survival was 45% for the control arm versus 26% for the investigational arm (Cox-p = 0.012) and overall survival 58% vs. 33%, respectively (p = 0.009). AML and infectious complications accounted for an increased death rate in the investigational arm. Irrespective of treatment, MRD status after two cycles appeared to be correlated with survival. We conclude that the addition of selinexor to standard chemotherapy does negatively affect the therapeutic outcome of elderly AML patients. (Netherlands Trial Registry number NL5748 (NTR5902), www.trialregister.nl ).

Published
2022

14. P1209: INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS

Author

Meeuwes, F. O., primary, Brink, M., additional, Van der Poel, M. W., additional, Kersten, M. J., additional, Wondergem, M. J., additional, Mutsaers, P. G., additional, Böhmer, L. H., additional, Woei-A-Jin, F. J. S. H., additional, Visser, O., additional, Oostvogels, R., additional, Jansen, P. M., additional, Plattel, W. J., additional, Huls, G. A., additional, Vermaat, J. S., additional, and Nijland, M., additional

Published
2022
Full Text
View/download PDF

15. P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY

Author

Doorduijn, J., primary, Issa, S., additional, van der Holt, B., additional, Minnema, M., additional, Seute, T., additional, Durian, M., additional, Cull, G., additional, van der Poel, M., additional, Stevens, W., additional, Zijlstra, J., additional, Nijland, M., additional, Mason, K., additional, Beeker, A., additional, Brandsma, D., additional, van den Bent, M., additional, Gonzalez, M., additional, de Jong, D., additional, and Bromberg, J., additional

Published
2022
Full Text
View/download PDF

16. P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE

Author

Spanjaart, A. M., primary, Pennings, E., additional, Mutsaers, P., additional, van Dorp, S., additional, Jak, M., additional, van Doesem, J., additional, de Boer, J., additional, Vermaat, J., additional, Sijs-Szabo, A., additional, van der Poel, M., additional, Kuipers, I., additional, Chamuleau, M., additional, Nijhof, I., additional, Minnema, M., additional, Lugtenburg, P., additional, van Meerten, T., additional, and Kersten, M. J., additional

Published
2022
Full Text
View/download PDF

17. P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS

Author

de Jonge, V., primary, Duetz, C., additional, Bruins, W., additional, van Werkhoven, E., additional, Nijland, M., additional, de Heer, K., additional, van der Poel, M., additional, Sandberg, Y., additional, Klerk, C., additional, de Jong, D., additional, Zijlstra, J., additional, Kersten, M. J., additional, Mutis, T., additional, and Chamuleau, M., additional

Published
2022
Full Text
View/download PDF

18. Single-cell mass cytometry reveals complex myeloid cell composition in active lesions of progressive multiple sclerosis

Author

Böttcher, C., van der Poel, M., Fernández-Zapata, C., Schlickeiser, S., Leman, J.K.H., Hsiao, C.-C., Mizee, M.R., Adelia, Vincenten, M.C.J., Kunkel, D., Huitinga, I., Hamann, J., Priller, J., Netherlands Institute for Neuroscience (NIN), Graduate School, AII - Inflammatory diseases, Experimental Immunology, and Structural and Functional Plasticity of the nervous system (SILS, FNWI)

Subjects
methods [Cell Separation], methods [Single-Cell Analysis], Research, methods [Flow Cytometry], Brain, Cell Separation, Multiple Sclerosis, Chronic Progressive, Flow Cytometry, pathology [Multiple Sclerosis, Chronic Progressive], lcsh:RC346-429, Active lesion, pathology [Brain], Myeloid cells, Humans, Myeloid Cells, Mass cytometry, ddc:610, Microglia, Single-Cell Analysis, Progressive multiple sclerosis, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, lcsh:Neurology. Diseases of the nervous system
Abstract

Myeloid cells contribute to inflammation and demyelination in the early stages of multiple sclerosis (MS), but it is still unclear to what extent these cells are involved in active lesion formation in progressive MS (PMS). Here, we have harnessed the power of single-cell mass cytometry (CyTOF) to compare myeloid cell phenotypes in active lesions of PMS donors with those in normal-appearing white matter from the same donors and control white matter from non-MS donors. CyTOF measurements of a total of 74 targeted proteins revealed a decreased abundance of homeostatic and TNFhi microglia, and an increase in highly phagocytic and activated microglia states in active lesions of PMS donors. Interestingly, in contrast to results obtained from studies of the inflammatory early disease stages of MS, infiltrating monocyte-derived macrophages were scarce in active lesions of PMS, suggesting fundamental differences of myeloid cell composition in advanced stages of PMS.

Published
2020
Full Text
View/download PDF

22. Relief of Symptoms and Quality of Life after Conservative versus Surgical Treatment of Benign Liver Tumors (CONSULT): A Retrospective Propensity Score Matched Study

Author

van Rosmalen, B., primary, Furumaya, A., additional, de Graeff, J.J., additional, van der Poel, M., additional, Ramsoekh, S., additional, Kazemier, G., additional, Verheij, J., additional, Takkenberg, B., additional, Besselink, M., additional, Erdmann, J., additional, and van Gulik, T., additional

Published
2022
Full Text
View/download PDF

24. Comparing practice and outcome of laparoscopic liver resection between high-volume expert centres and nationwide low-to-medium volume centres

Author

Görgec, B, primary, Fichtinger, R S, additional, Ratti, F, additional, Aghayan, D, additional, Van der Poel, M J, additional, Al-Jarrah, R, additional, Armstrong, T, additional, Cipriani, F, additional, Fretland, Å A, additional, Suhool, A, additional, Bemelmans, M, additional, Bosscha, K, additional, Braat, A E, additional, De Boer, M T, additional, Dejong, C H C, additional, Doornebosch, P G, additional, Draaisma, W A, additional, Gerhards, M F, additional, Gobardhan, P D, additional, Hagendoorn, J, additional, Kazemier, G, additional, Klaase, J, additional, Leclercq, W K G, additional, Liem, M S, additional, Lips, D J, additional, Marsman, H A, additional, Mieog, J S D, additional, Molenaar, Q I, additional, Nieuwenhuijs, V B, additional, Nota, C L, additional, Patijn, G A, additional, Rijken, A M, additional, Slooter, G D, additional, Stommel, M W J, additional, Swijnenburg, R J, additional, Tanis, P J, additional, Te Riele, W W, additional, Terkivatan, T, additional, Van den Tol, P M P, additional, Van den Boezem, P B, additional, Van der Hoeven, J A, additional, Vermaas, M, additional, Edwin, B, additional, Aldrighetti, L A, additional, Van Dam, R M, additional, Abu Hilal, M, additional, and Besselink, M G, additional

Published
2021
Full Text
View/download PDF

28. Extent of radiological response does not reflect survival in primary central nervous system lymphoma

Author

Meulen, M. van der, Postma, A.A., Smits, M., Bakunina, K., Minnema, M.C., Seute, T., Cull, G., Enting, R.H., Poel, M., Stevens, W.B.C., Brandsma, D., Beeker, A., Doorduijn, J.K., Issa, S., Bent, M.J. van den, Bromberg, J.E., Meulen, M. van der, Postma, A.A., Smits, M., Bakunina, K., Minnema, M.C., Seute, T., Cull, G., Enting, R.H., Poel, M., Stevens, W.B.C., Brandsma, D., Beeker, A., Doorduijn, J.K., Issa, S., Bent, M.J. van den, and Bromberg, J.E.

Abstract

Contains fulltext : 245053.pdf (Publisher’s version ) (Open Access), BACKGROUND: In primary central nervous system lymphoma (PCNSL), small enhancing lesions can persist after treatment. It is unknown whether a difference in response category (complete response [CR], complete response unconfirmed [CRu], or partial response [PR]) reflects survival. We aimed to determine the value of a central radiology review on response assessment and whether the extent of response influenced progression-free and/or overall survival. METHODS: All patients in the HOVON 105/ALLG NHL 24 study with at least a baseline MRI and one MRI made for response evaluation available for central review were included. Tumor measurements were done by 2 independent central reviewers, disagreements were adjudicated by a third reviewer. Crude agreement and interobserver agreement (Cohen's kappa) were calculated. Differences in progression-free and overall survival between different categories of response at the end-of-protocol-treatment were assessed by the log-rank test in a landmark survival-analysis. RESULTS: Agreement between the central reviewers was 61.7% and between local and central response assessment was 63.0%. Cohen's kappa's, which corrects for expected agreement, were 0.44 and 0.46 (moderate), respectively. Progression agreement or not was 93.3% (kappa 0.87) between local and central response assessment. There were no significant differences in progression-free and overall survival between patients with CR, CRu, or PR at the end-of-protocol-treatment, according to both local and central response assessment. CONCLUSIONS: Reliability of response assessment (CR/CRu/PR) is moderate even by central radiology review and these response categories do not reliably predict survival. Therefore, primary outcome in PCNSL studies should be survival rather than CR or CR/CRu-rate.

Published
2021

29. Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial

Author

Oerlemans, S., Arts, L.P.J., Kieffer, J.M., Prins, J.B., Hoogendoorn, M., Poel, M., Koster, A., Lensen, C., Stevens, W.B.C., Issa, D., Pruijt, J.F., Oosterveld, M., Griend, R. van der, Nijziel, M., Tick, L., Posthuma, E.F., Poll-Franse, L.V. van de, Oerlemans, S., Arts, L.P.J., Kieffer, J.M., Prins, J.B., Hoogendoorn, M., Poel, M., Koster, A., Lensen, C., Stevens, W.B.C., Issa, D., Pruijt, J.F., Oosterveld, M., Griend, R. van der, Nijziel, M., Tick, L., Posthuma, E.F., and Poll-Franse, L.V. van de

Abstract

Contains fulltext : 244124.pdf (Publisher’s version ) (Open Access), BACKGROUND: There has been a cultural shift toward patient engagement in health, with a growing demand from patients to access their results. OBJECTIVE: The Lymphoma Intervention (LIVE) trial is conducted to examine the impact of return of individual patient-reported outcome (PRO) results and a web-based self-management intervention on psychological distress, self-management, satisfaction with information, and health care use in a population-based setting. METHODS: Return of PRO results included comparison with age- and sex-matched peers and was built into the Patient-Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship registry. The self-management intervention is an adaptation of a fully automated evidence-based intervention for breast cancer survivors. Patients with lymphoma who completed the web-based questionnaire were equally randomized to care as usual, return of PRO results, and return of PRO results plus self-management intervention. Patients completed questionnaires 9 to 18 months after diagnosis (T0; n=227), 4 months (T1; n=190), 12 months (T2; n=170), and 24 months (T3; n=98). RESULTS: Of all invited patients, 51.1% (456/892) responded and web-based participants (n=227) were randomly assigned to care as usual (n=76), return of PRO results (n=74), or return of PRO results and access to Living with lymphoma (n=77). Return of PRO results was viewed by 76.7% (115/150) of those with access. No statistically significant differences were observed for psychological distress, self-management, satisfaction with information provision, and health care use between patients who received PRO results and those who did not (P>.05). Use of the self-management intervention was low (2/76, 3%), and an effect could therefore not be determined. CONCLUSIONS: Return of individual PRO results seems to meet patients' wishes but had no beneficial effects on patient outcome. No negative effects were found when individual PRO results were disclosed

Published
2021

30. Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds

Author

Janssen, J. (Jeroen), Löwenberg, B. (Bob), Manz, M. (Markus), Bargetzi, M. (Mario), Biemond, B.J. (Bart), Borne, P.A.K. (Peter) von dem, Breems, D.A. (Dimitri), Brouwer, R.E. (Rolf), Chalandon, Y. (Yves), Deeren, D. (Dries), Efthymiou, A. (Anna), Gjertsen, B.-T. (Bjørn-Tore), Graux, C. (Carlos), Gregor, M. (Michael), Heim, D. (Dominik), Hess, U. (Urs), Hoogendoorn, M. (Mels), Jaspers, A. (Aurelie), Jie, A. (Asiong), Jongen-Lavrencic, M. (Mojca), Klein, S. (Saskia), Klift, M. (Marjolein) van der, Kuball, J. (Jürgen), van Lammeren - Venema, D. (Danielle), Legdeur, M.C.J.C. (M. C J C), Loosdrecht, A.A. (Arjan) van de, Maertens, J. (Johan), Kooy, M.M. (Marinus van Marwijk), Moors, I. (Ine), Nijziel, M.R. (Marten), van Obbergh, F. (Florence), Oosterveld, M. (Margriet), Pabst, T. (Thomas), van der Poel, M. (Marjolein), Sinnige, H. (Harm), Spertini, O. (Olivier), Terpstra, W. (Wim), Tick, L.W. (Lidwine), Velden, W.J.F.M. (Walter) van der, Vekemans, M.-C. (Marie-Christiane), Vellenga, E. (Edo), Weerdt, O. (Okke) de, Westerweel, P. (Peter), Stussi, G. (Georg), Norden, Y. (Yvette) van, Ossenkoppele, G.J. (Gert), Janssen, J. (Jeroen), Löwenberg, B. (Bob), Manz, M. (Markus), Bargetzi, M. (Mario), Biemond, B.J. (Bart), Borne, P.A.K. (Peter) von dem, Breems, D.A. (Dimitri), Brouwer, R.E. (Rolf), Chalandon, Y. (Yves), Deeren, D. (Dries), Efthymiou, A. (Anna), Gjertsen, B.-T. (Bjørn-Tore), Graux, C. (Carlos), Gregor, M. (Michael), Heim, D. (Dominik), Hess, U. (Urs), Hoogendoorn, M. (Mels), Jaspers, A. (Aurelie), Jie, A. (Asiong), Jongen-Lavrencic, M. (Mojca), Klein, S. (Saskia), Klift, M. (Marjolein) van der, Kuball, J. (Jürgen), van Lammeren - Venema, D. (Danielle), Legdeur, M.C.J.C. (M. C J C), Loosdrecht, A.A. (Arjan) van de, Maertens, J. (Johan), Kooy, M.M. (Marinus van Marwijk), Moors, I. (Ine), Nijziel, M.R. (Marten), van Obbergh, F. (Florence), Oosterveld, M. (Margriet), Pabst, T. (Thomas), van der Poel, M. (Marjolein), Sinnige, H. (Harm), Spertini, O. (Olivier), Terpstra, W. (Wim), Tick, L.W. (Lidwine), Velden, W.J.F.M. (Walter) van der, Vekemans, M.-C. (Marie-Christiane), Vellenga, E. (Edo), Weerdt, O. (Okke) de, Westerweel, P. (Peter), Stussi, G. (Georg), Norden, Y. (Yvette) van, and Ossenkoppele, G.J. (Gert)

Abstract

Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66–81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg (n = 116), days 1–21. In the second cycle, patients received cytarabine 1000 mg/m2 twice daily on days 1-6 with or without tosedostat. CR/CRi rates in the 2 arms were not significantly different (69% (95% C.I. 60–77%) vs 64% (55–73%), respectively). At 24 months, event-free survival (EFS) was 20% for the standard arm versus 12% for the tosedostat arm (Cox-p = 0.01) and overall survival (OS) 33% vs 18% respectively (p = 0.006). Infectious complications accounted for an increased early death rate in the tosedostat arm. Atrial fibrillation wa

Published
2021
Full Text
View/download PDF

31. Quintilian and Declamation

Author

Poel, M. van der, Edwards, M., Murphy, J., Breij, B.M.C., Poel, M. van der, Edwards, M., Murphy, J., and Breij, B.M.C.

Abstract

Item does not contain fulltext

Published
2021

32. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, B, Ahn, KW, Fretham, C, Beitinjaneh, A, Bashey, A, Pawarode, A, Wirk, B, Scott, BL, Savani, BN, Bredeson, C, Weisdorf, D, Marks, DI, Rizzieri, D, Copelan, E, Hildebrandt, GC, Hale, GA, Murthy, HS, Lazarus, HM, Cerny, J, Liesveld, JL, Yared, JA, Yves-Cahn, J, Szer, J, Verdonck, LF, MahmoudAljurf, van der Poel, M, Litzow, M, Kalaycio, M, Grunwald, MR, AngelDiaz, M, Sabloff, M, Kharfan-Dabaja, MA, Majhail, NS, Farhadfar, N, Reshef, R, Olsson, RF, Gale, RP, Nakamura, R, Seo, S, Chhabra, S, Hashmi, S, Farhan, S, Ganguly, S, Nathan, S, TaigaNishihori, Jain, T, VaibhavAgrawal, Bacher, U, Popat, U, Saber, W, Oran, B, Ahn, KW, Fretham, C, Beitinjaneh, A, Bashey, A, Pawarode, A, Wirk, B, Scott, BL, Savani, BN, Bredeson, C, Weisdorf, D, Marks, DI, Rizzieri, D, Copelan, E, Hildebrandt, GC, Hale, GA, Murthy, HS, Lazarus, HM, Cerny, J, Liesveld, JL, Yared, JA, Yves-Cahn, J, Szer, J, Verdonck, LF, MahmoudAljurf, van der Poel, M, Litzow, M, Kalaycio, M, Grunwald, MR, AngelDiaz, M, Sabloff, M, Kharfan-Dabaja, MA, Majhail, NS, Farhadfar, N, Reshef, R, Olsson, RF, Gale, RP, Nakamura, R, Seo, S, Chhabra, S, Hashmi, S, Farhan, S, Ganguly, S, Nathan, S, TaigaNishihori, Jain, T, VaibhavAgrawal, Bacher, U, Popat, U, and Saber, W

Published
2021

34. Quintilian. The Biographical Tradition

Author

Poel, M. van der, Edwards, M., Murphy, J., Poel, M.G.M. van der, Murphy, J.J., Poel, M. van der, Edwards, M., Murphy, J., Poel, M.G.M. van der, and Murphy, J.J.

Abstract

Item does not contain fulltext

Published
2021

35. Quintilian’s Underlying Educational Programme

Author

Poel, M. van der, Edwards, M., Murphy, J., Poel, M.G.M. van der, Poel, M. van der, Edwards, M., Murphy, J., and Poel, M.G.M. van der

Abstract

Item does not contain fulltext

Published
2021

36. Low Dimensional State Representation Learning with Robotics Priors in Continuous Action Spaces

Author

Botteghi, N., Alaa, K., Poel, M., Sirmacek, Beril, Brune, C., Mersha, A., Stramigioli, S., Botteghi, N., Alaa, K., Poel, M., Sirmacek, Beril, Brune, C., Mersha, A., and Stramigioli, S.

Abstract

Reinforcement learning algorithms have proven to be capable of solving complicated robotics tasks in an end-to-end fashion without any need for hand-crafted features or policies. Especially in the context of robotics, in which the cost of real-world data is usually extremely high, Reinforcement Learning solutions achieving high sample efficiency are needed. In this paper, we propose a framework combining the learning of a low-dimensional state representation, from high-dimensional observations coming from the robot's raw sensory readings, with the learning of the optimal policy, given the learned state representation. We evaluate our framework in the context of mobile robot navigation in the case of continuous state and action spaces. Moreover, we study the problem of transferring what learned in the simulated virtual environment to the real robot without further retraining using real-world data in the presence of visual and depth distractors, such as lighting changes and moving obstacles. A video of our experiments can be found at: https://youtu.be/rUdGPKr2Wuo.

Published
2021
Full Text
View/download PDF

37. Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds

Author

Janssen, J, Löwenberg, Bob, Manz, M, Bargetzi, M, Biemond, B, van den Borne, P, Breems, D, Brouwer, R, Chalandon, Y, Deeren, D, Efthymiou, A, Gjertsen, BT, Graux, C, Gregor, M, Heim, D, Hess, U, Hoogendoorn, M, Jaspers, A, Jie, A, Jongen - Lavrencic, Mojca, Klein, S, van der Klift, Maarten, Kuball, J, van Lammeren-Venema, D, Legdeur, MC, van de Loosdrecht, A, Maertens, J, Kooy, MM, Moors, I, Nijziel, M, van Obbergh, F, Oosterveld, M, Pabst, T, Poel, M, Sinnige, H, Spertini, O, Terpstra, W, Tick, L, van der Velden, W, Vekemans, MC, Vellenga, E, de Weerdt, O, Westerweel, P, Stüssi, G, van Norden, Yvette, Ossenkoppele, G, Janssen, J, Löwenberg, Bob, Manz, M, Bargetzi, M, Biemond, B, van den Borne, P, Breems, D, Brouwer, R, Chalandon, Y, Deeren, D, Efthymiou, A, Gjertsen, BT, Graux, C, Gregor, M, Heim, D, Hess, U, Hoogendoorn, M, Jaspers, A, Jie, A, Jongen - Lavrencic, Mojca, Klein, S, van der Klift, Maarten, Kuball, J, van Lammeren-Venema, D, Legdeur, MC, van de Loosdrecht, A, Maertens, J, Kooy, MM, Moors, I, Nijziel, M, van Obbergh, F, Oosterveld, M, Pabst, T, Poel, M, Sinnige, H, Spertini, O, Terpstra, W, Tick, L, van der Velden, W, Vekemans, MC, Vellenga, E, de Weerdt, O, Westerweel, P, Stüssi, G, van Norden, Yvette, and Ossenkoppele, G

Abstract

Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66–81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg (n = 116), days 1–21. In the second cycle, patients received cytarabine 1000 mg/m2 twice daily on days 1-6 with or without tosedostat. CR/CRi rates in the 2 arms were not significantly different (69% (95% C.I. 60–77%) vs 64% (55–73%), respectively). At 24 months, event-free survival (EFS) was 20% for the standard arm versus 12% for the tosedostat arm (Cox-p = 0.01) and overall survival (OS) 33% vs 18% respectively (p = 0.006). Infectious complications accounted for an increased early death rate in the tosedostat arm. Atrial fibrillation was more common in the tosedostat arm as well. The results of the present study show that the addition of tosedostat to standard chemotherapy does negatively affect the therapeutic outcome of elderly AML patients.

Published
2021

38. Comparing practice and outcome of laparoscopic liver resection between high-volume expert centres and nationwide low-to-medium volume centres

Author

Zorgeenheid Vaatchirurgie Zorg, MS CGO, Cancer, Görgec, B., Fichtinger, R. S., Ratti, F., Aghayan, D., Van der Poel, M. J., Al-Jarrah, R., Armstrong, T., Cipriani, F., Fretland, ÅA, Suhool, A., Bemelmans, M., Bosscha, K., Braat, A. E., De Boer, M. T., Dejong, C. H.C., Doornebosch, P. G., Draaisma, W. A., Gerhards, M. F., Gobardhan, P. D., Hagendoorn, J., Kazemier, G., Klaase, J., Leclercq, W. K.G., Liem, M. S., Lips, D. J., Marsman, H. A., Mieog, J. S.D., Molenaar, Q. I., Nieuwenhuijs, V. B., Nota, C. L., Patijn, G. A., Rijken, A. M., Slooter, G. D., Stommel, M. W.J., Swijnenburg, R. J., Tanis, P. J., Te Riele, W. W., Terkivatan, T., Van den Tol, P. M.P., Van den Boezem, P. B., Van der Hoeven, J. A., Vermaas, M., Edwin, B., Aldrighetti, L. A., Van Dam, R. M., Abu Hilal, M., Besselink, M. G., Zorgeenheid Vaatchirurgie Zorg, MS CGO, Cancer, Görgec, B., Fichtinger, R. S., Ratti, F., Aghayan, D., Van der Poel, M. J., Al-Jarrah, R., Armstrong, T., Cipriani, F., Fretland, ÅA, Suhool, A., Bemelmans, M., Bosscha, K., Braat, A. E., De Boer, M. T., Dejong, C. H.C., Doornebosch, P. G., Draaisma, W. A., Gerhards, M. F., Gobardhan, P. D., Hagendoorn, J., Kazemier, G., Klaase, J., Leclercq, W. K.G., Liem, M. S., Lips, D. J., Marsman, H. A., Mieog, J. S.D., Molenaar, Q. I., Nieuwenhuijs, V. B., Nota, C. L., Patijn, G. A., Rijken, A. M., Slooter, G. D., Stommel, M. W.J., Swijnenburg, R. J., Tanis, P. J., Te Riele, W. W., Terkivatan, T., Van den Tol, P. M.P., Van den Boezem, P. B., Van der Hoeven, J. A., Vermaas, M., Edwin, B., Aldrighetti, L. A., Van Dam, R. M., Abu Hilal, M., and Besselink, M. G.

Published
2021

42. IMPACT OF RITUXIMAB ON TREATMENT OUTCOMES OF PATIENTS WITH ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA; A POPULATION‐BASED ANALYSIS

Author

Meeuwes, F. O., primary, Brink, M., additional, van der Poel, M. W.M., additional, Kersten, M. J., additional, Wondergem, Mariël., additional, Mutsaers, P. G.N.J., additional, Böhmer, L. H., additional, Woei‐A‐Jin, S., additional, Visser, O., additional, Oostvogels, R., additional, Janssen, P. M., additional, Huls, G. A., additional, Vermaat, J. S.P., additional, and Nijland, M., additional

Published
2021
Full Text
View/download PDF

43. SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL.

Author

Thieblemont, C., Karimi, Y., Jurczak, W., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., van der Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Cottereau, A., Al Tabaa, Y., Stirner, M. Cota, and Liu, Y.

Subjects
LYMPHOMAS, BISPECIFIC antibodies
Abstract

B Introduction: b Outcomes are poor for patients with relapsed/refractory ( I R i / I R i ) large B-cell lymphoma (LBCL). SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL. [Extracted from the article]

Published
2023
Full Text
View/download PDF

44. Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions

Author

Fransen, N.L. (Nina L.), Hsiao, C.-C. (Cheng-Chih), van der Poel, M. (Marlijn), Engelenburg, H.J. (Hendrik J.), Verdaasdonk, K. (Kim), Vincenten, M.C.J. (Maria C J), Remmerswaal, D. (Daniëlle), Kuhlmann, T. (Tanja), Mason, M.R.J. (Matthew R J), Hamann, J. (Jörg), Smolders, J. (Joost), Huitinga, I. (Inge), Fransen, N.L. (Nina L.), Hsiao, C.-C. (Cheng-Chih), van der Poel, M. (Marlijn), Engelenburg, H.J. (Hendrik J.), Verdaasdonk, K. (Kim), Vincenten, M.C.J. (Maria C J), Remmerswaal, D. (Daniëlle), Kuhlmann, T. (Tanja), Mason, M.R.J. (Matthew R J), Hamann, J. (Jörg), Smolders, J. (Joost), and Huitinga, I. (Inge)

Abstract

Multiple sclerosis is a chronic inflammatory, demyelinating disease, although it has been suggested that in the progressive late phase, inflammatory lesion activity declines. We recently showed in the Netherlands Brain Bank multiple sclerosis-autopsy cohort considerable ongoing inflammatory lesion activity also at the end stage of the disease, based on microglia/macrophage activity. We have now studied the role of T cells in this ongoing inflammatory lesion activity in chronic multiple sclerosis autopsy cases. We quantified T cells and perivascular T-cell cuffing at a standardized location in the medulla oblongata in 146 multiple sclerosis, 20 neurodegenerative control and 20 non-neurological control brain donors. In addition, we quantified CD3+, CD4+, and CD8+ T cells in 140 subcortical white matter lesions. The location of CD8+ T cells in either the perivascular space or the brain parenchyma was determined using CD8/laminin staining and confocal imaging. Finally, we analysed CD8+ T cells, isolated from fresh autopsy tissues from subcortical multiple sclerosis white matter lesions (n = 8), multiple sclerosis normal-app

Published
2020
Full Text
View/download PDF

47. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Author

UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, Carlos, Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, Marie-Christiane, van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Violaine, Sonet, Anne, UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, Carlos, Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, Marie-Christiane, van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Violaine, and Sonet, Anne

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

48. Low dimensional state representation learning with reward-shaped priors

Author

Botteghi, N., Obbink, R., Geijs, D., Poel, M., Sirmacek, Beril, Brune, C., Mersha, A., Stramigioli, S., Botteghi, N., Obbink, R., Geijs, D., Poel, M., Sirmacek, Beril, Brune, C., Mersha, A., and Stramigioli, S.

Abstract

Reinforcement Learning has been able to solve many complicated robotics tasks without any need for feature engineering in an end-to-end fashion. However, learning the optimal policy directly from the sensory inputs, i.e the observations, often requires processing and storage of a huge amount of data. In the context of robotics, the cost of data from real robotics hardware is usually very high, thus solutions that achieve high sample-efficiency are needed. We propose a method that aims at learning a mapping from the observations into a lower-dimensional state space. This mapping is learned with unsupervised learning using loss functions shaped to incorporate prior knowledge of the environment and the task. Using the samples from the state space, the optimal policy is quickly and efficiently learned. We test the method on several mobile robot navigation tasks in a simulation environment and also on a real robot. A video of our experiments can be found at: https://youtu.be/dgWxmfSv95U.

Published
2020
Full Text
View/download PDF

49. Reinforcement learning helps slam : Learning to build maps

Author

Botteghi, N., Sirmacek, Beril, Schulte, R., Poel, M., Brune, C., Botteghi, N., Sirmacek, Beril, Schulte, R., Poel, M., and Brune, C.

Abstract

In this research, we investigate the use of Reinforcement Learning (RL) for an effective and robust solution for exploring unknown and indoor environments and reconstructing their maps. We benefit from a Simultaneous Localization and Mapping (SLAM) algorithm for real-time robot localization and mapping. Three different reward functions are compared and tested in different environments with growing complexity. The performances of the three different RL-based path planners are assessed not only on the training environments, but also on an a priori unseen environment to test the generalization properties of the policies. The results indicate that RL-based planners trained to maximize the coverage of the map are able to consistently explore and construct the maps of different indoor environments.

Published
2020
Full Text
View/download PDF

50. Comparing Practice and Outcome of Laparoscopic Liver Resection Between High-volume Expert Centres and Nationwide Low-medium Volume Centres

Author

Görgec, B., primary, Fichtinger, R., additional, Ratti, F., additional, Aghayan, D., additional, van der Poel, M., additional, Al-Jarrah, R., additional, Armstrong, T., additional, Cipriani, F., additional, Fretland, Å., additional, Suhool, A., additional, Bemelmans, M., additional, Bosscha, K., additional, Braat, A., additional, de Boer, M., additional, Dejong, C., additional, Doornebosch, P., additional, Draaisma, W., additional, Gerhards, M., additional, Gobardhan, P., additional, Hagendoorn, J., additional, Kazemier, G., additional, Klaase, J., additional, Leclerq, W., additional, Liem, M., additional, Lips, D., additional, Marsman, H., additional, Mieog, J., additional, Molenaar, Q., additional, Nieuwenhuijs, V., additional, Nota, C., additional, Patijn, G., additional, Rijken, A., additional, Slooter, G., additional, Stommel, M., additional, Swijnenburg, R., additional, Tanis, P., additional, Riele, W. Te, additional, Terkivatan, T., additional, van den Tol, P., additional, van den Boezem, P., additional, van der Hoeven, J., additional, Vermaas, M., additional, Edwin, B., additional, Aldrighetti, L., additional, van Dam, R., additional, Hilal, M. Abu, additional, and Besselink, M., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results